



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT  
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON  
June 15, 2005

*Theresa M. Munro*

Signature of Person Mailing this Document

*June 15, 2005*

DATE

Attorney Docket No. P31220X2C2R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard, et al.  
Serial No.: 10/024,858  
Group Art No.: 1625  
Filed: December 18, 2001  
Customer No: 20462

For: PAROXETINE CONTROLLED RELEASE COMPOSITIONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449.  
Copies of each are enclosed.

06/22/2005 HARDEL1 00000119 192570 10024858  
01 FC:1806 160.00 DA

Serial No.: 10/024,858  
Group Art Unit No.: 1625

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Wayne J. Dustman", with a long horizontal flourish extending to the right.

Wayne J. Dustman  
Attorney for Applicants  
Registration No. 32,917

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5023  
Facsimile (610) 270-5090

n:\wjd\paroxetine\p31220 paxil cr\ids letter based on c. rugg.doc



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31220X2C2R2	SERIAL NO. 10/024,858
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		APPLICANT Leonard, et al.	
		FILING DATE December 18, 2001	GROUP 1625

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6, 168, 805	01/2001	Hein, et al.			
	5, 776, 969	07/1998	James			
	5, 668, 134	09/1997	Limstra, et al.			
	5, 811, 436	09/1998	Leonard, et al.			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 95/20964	08/1995	WIPO				
	WO 97/18798	05/1997	WIPO				
	WO 91/13612	09/1991	WIPO				
	0 714 663	06/1996	EP				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Caley, et al., The Annals of Pharmacology, 1993, Vol. 27, pp. 1212-1222.
	FDA FOIA Materials, June 1993
	Lund, et al., Acta. Pharmacol. Toxicol., 1979, Vol. 44, pp. 289-295.
	Torii, et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 1991, Vol. 344, pp. 564-567.
	Gale, J. of Pediatric Gast. and Nutrition, 1995, Vol. 21, Suppl. 1, pp. S22-S28.
	Bailey, et al., J. of Psychopharm., 1995, Vol. 9, No. 2, pp. 137-141.
	Finely, The Annals of Pharmacotherapy, 1994, Vol. 28, pp.1359-1369.
	J. van Harten, et al., Neuropsychopharmacology, 1994, Vol. 10, No. 35, pp. 104S.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\wjd\paroxetine\p31220 paxil cr\supp. 1449 based on c.rugg.doc